
**WHAT IS CLAIMED IS:**

1. A compound of the formula:




(I),

wherein:

$R_1$ is hydrogen; or

$alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, a monovalent amino protecting group, or $-C(O)R_4$, wherein:

$R_4$ is hydrogen; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $cycloalkoxy_{(C\leq 8)}$, $cycloalkylamino_{(C\leq 8)}$, $heterocyclo\text{-}alkyl_{(C\leq 8)}$, or a substituted version of any one of these groups; or

$R_1$ and $R_2$ are taken together as defined below;

$R_2$ is $alkyl_{(C\leq 8)}$ or substituted $alkyl_{(C\leq 8)}$; or

$-NR_cR_d$, wherein:

$R_c$ and $R_d$ are each independently hydrogen, $alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, $acyl_{(C\leq 8)}$, substituted $acyl_{(C\leq 8)}$, or a monovalent amino protecting group; or

$-C(O)R_5$, wherein:

$R_5$ is hydrogen; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $cycloalkoxy_{(C\leq 8)}$, $cycloalkylamino_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, or a substituted version of any one of these groups; or

$R_2$ and $R_1$ are taken together as defined below;


$R_1$ and $R_2$, when taken together with the nitrogen atom of the $-NR_1R_2$ group, is *N*-heteroaryl$_{(C\leq 8)}$, substituted *N*-heteroaryl$_{(C\leq 8)}$, *N*-heterocycloalkyl$_{(C\leq 8)}$, substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, or 3-oxo-1-(*t*-butoxycarbonyl)pyrazolidin-2-yl;

$R_3$ and $R_3'$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; and

$R_6$ is hydrogen, hydroxy, or amino; or

acyloxy$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, amido$_{(C\leq 8)}$, or a substituted version of any of these groups; or

a compound of the formula:




(II),

wherein:

$R_1$ is hydrogen; or

alkyl$_{(C\leq 8)}$ or substituted alkyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below;

$R_2$ is $-NR_cR_d$, wherein:

$R_c$ and $R_d$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, acyl$_{(C\leq 8)}$, substituted acyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below;

$R_1$ and $R_2$, when taken together with the nitrogen atom of the $-NR_1R_2$ group, is *N*-heteroaryl$_{(C\leq 8)}$, substituted *N*-heteroaryl$_{(C\leq 8)}$, *N*-heterocycloalkyl$_{(C\leq 8)}$, substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, or 3-oxo-1-(*t*-butoxycarbonyl)pyrazolidin-2-yl;


$R_3$ and $R_3'$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; and

$R_6$ is hydrogen, hydroxy, or amino; or

acyloxy$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, amido$_{(C\leq 8)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt of either of these formulae.

2. The compound of claim 1, wherein the compound is further defined as:




(I),

wherein:

$R_1$ is hydrogen; or

alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, a monovalent amino protecting group, or −C(O)$R_4$, wherein:

$R_4$ is hydrogen; or

alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocyclo-alkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups; or

$R_1$ and $R_2$ are taken together as defined below;

$R_2$ is alkyl$_{(C\leq 8)}$ or substituted alkyl$_{(C\leq 8)}$; or

−N$R_c$$R_d$, wherein:

$R_c$ and $R_d$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, acyl$_{(C\leq 8)}$, substituted acyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

−C(O)$R_5$, wherein:

$R_5$ is hydrogen; or

alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocycloalkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups; or

$R_2$ and $R_1$ are taken together as defined below;

$R_1$ and $R_2$, when taken together with the nitrogen atom of the $-NR_1R_2$ group, is *N*-heteroaryl$_{(C\leq 8)}$, substituted *N*-heteroaryl$_{(C\leq 8)}$, *N*-heterocycloalkyl$_{(C\leq 8)}$, substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, or 3-oxo-1-(*t*-butoxycarbonyl)pyrazolidin-2-yl;


$R_3$ and $R_3'$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; and

$R_6$ is hydrogen, hydroxy, or amino; or

acyloxy$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, amido$_{(C\leq 8)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt thereof.

3. The compound of either claim 1 or claim 2, wherein the compound is further defined as:




(I-A),

wherein:

$R_1$ is hydrogen; or

alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, a monovalent amino protecting group, or $-C(O)R_4$, wherein:

$R_4$ is hydrogen; or

alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocyclo-alkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups; or

$R_1$ and $R_2$ are taken together as defined below;

$R_2$ is alkyl$_{(C\leq 8)}$ or substituted alkyl$_{(C\leq 8)}$; or

$-NR_cR_d$, wherein:

$R_c$ and $R_d$ are each independently hydrogen, $alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, $acyl_{(C\leq 8)}$, substituted $acyl_{(C\leq 8)}$, or a monovalent amino protecting group; or

$-C(O)R_5$, wherein:

$R_5$ is hydrogen; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $cycloalkoxy_{(C\leq 8)}$, $cycloalkylamino_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, or a substituted version of any one of these groups; or

$R_2$ and $R_1$ are taken together as defined below;


$R_1$ and $R_2$, when taken together with the nitrogen atom of the $-NR_1R_2$ group, is *N*-$heteroaryl_{(C\leq 8)}$, substituted *N*-$heteroaryl_{(C\leq 8)}$, *N*-$heterocycloalkyl_{(C\leq 8)}$, substituted *N*-$heterocycloalkyl_{(C\leq 8)}$, or 3-oxo-1-(*t*-butoxycarbonyl)pyrazolidin-2-yl; and

$R_6$ is hydrogen, hydroxy, or amino; or

$acyloxy_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $amido_{(C\leq 8)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt thereof.

4. The compound according to any one of claims 1-3, wherein the compound is further defined as:




(I-B),

wherein:

$R_1$ is hydrogen; or

$alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, a monovalent amino protecting group, or $-C(O)R_4$, wherein:

$R_4$ is hydrogen; or

alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocyclo-alkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups; or

$R_1$ and $R_2$ are taken together as defined below;

$R_2$ is alkyl$_{(C\leq 8)}$ or substituted alkyl$_{(C\leq 8)}$; or

$-NR_cR_d$, wherein:

$R_c$ and $R_d$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, acyl$_{(C\leq 8)}$, substituted acyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

$-C(O)R_5$, wherein:

$R_5$ is hydrogen; or


alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocycloalkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups; or

$R_2$ and $R_1$ are taken together as defined below; and

$R_1$ and $R_2$, when taken together with the nitrogen atom of the $-NR_1R_2$ group, is *N*-heteroaryl$_{(C\leq 8)}$, substituted *N*-heteroaryl$_{(C\leq 8)}$, *N*-heterocycloalkyl$_{(C\leq 8)}$, substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, or 3-oxo-1-(*t*-butoxycarbonyl)pyrazolidin-2-yl;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, wherein the compound is further defined as:




(II),

wherein:

$R_1$ is hydrogen; or

alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below;

$R_2$ is $-NR_cR_d$, wherein:

$R_c$ and $R_d$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, acyl$_{(C\leq 8)}$, substituted acyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below;

$R_1$ and $R_2$, when taken together with the nitrogen atom of the $-NR_1R_2$ group, is *N*-heteroaryl$_{(C\leq 8)}$, substituted *N*-heteroaryl$_{(C\leq 8)}$, *N*-heterocycloalkyl$_{(C\leq 8)}$, substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, or 3-oxo-1-(*t*-butoxycarbonyl)pyrazolidin-2-yl;


$R_3$ and $R_3'$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; and

$R_6$ is hydrogen, hydroxy, or amino; or

acyloxy$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, amido$_{(C\leq 8)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt thereof.

6. The compound of either claim 1 or claim 5, wherein the compound is further defined as:




(II),

wherein:

$R_1$ is hydrogen; or

alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below;


$R_2$ is $-NR_cR_d$, wherein:

$R_c$ and $R_d$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, acyl$_{(C\leq 8)}$, substituted acyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below;

$R_1$ and $R_2$, when taken together with the nitrogen atom of the $-NR_1R_2$ group, is *N*-heteroaryl$_{(C\leq 8)}$, substituted *N*-heteroaryl$_{(C\leq 8)}$, *N*-heterocycloalkyl$_{(C\leq 8)}$, or 3-oxo-1-(*t*-butoxycarbonyl)pyrazolidin-2-yl; or

substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:



or




,

wherein:

n is 0, 1, 2, or 3;

$R_a$ is hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; or

substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:



,

wherein:


the bond between atoms a and b is a single bond or a double bond;

m is 0, 1, 2, or 3; and


$X_1$ is $-CH_2-$, $-O-$, or $-N(R_b)-$, wherein:

$R_b$ is hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; or

substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:



or



,

wherein:

p is 0 or 1;

q is 0 or 1; and

$X_2$ is $-CH_2-$, $-O-$, or $-N(R_e)-$, wherein:

$R_e$ is hydrogen, $alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, or a monovalent amino protecting group;


$R_3$ and $R_3'$ are each independently hydrogen, $alkyl_{(C\leq 8)}$, or substituted $alkyl_{(C\leq 8)}$; and

$R_6$ is hydrogen, hydroxy, or amino; or

$acyloxy_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $amido_{(C\leq 8)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt thereof.

7. The compound according to any one of claims 1, 5, and 6, wherein the compound is further defined as:




(II-A),

wherein:

$R_1$ is hydrogen; or

$alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below;


$R_2$ is $-NR_cR_d$, wherein:

$R_c$ and $R_d$ are each independently hydrogen, $alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, $acyl_{(C\leq 8)}$, substituted $acyl_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below;

$R_1$ and $R_2$, when taken together with the nitrogen atom of the $-NR_1R_2$ group, is *N*-$heteroaryl_{(C\leq 8)}$, substituted *N*-$heteroaryl_{(C\leq 8)}$, *N*-$heterocycloalkyl_{(C\leq 8)}$, or 3-oxo-1-(*t*-butoxycarbonyl)pyrazolidin-2-yl; or

substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:




wherein:

n is 0, 1, 2, or 3;

$R_a$ is hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; or

substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:



wherein:


the bond between atoms a and b is a single bond or a double bond;

m is 0, 1, 2, or 3; and

$X_1$ is $-CH_2-$, $-O-$, or $-N(R_b)-$, wherein:

$R_b$ is hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; or

substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:



wherein:

p is 0 or 1;

q is 0 or 1; and

$X_2$ is $-CH_2-$, $-O-$, or $-N(R_e)-$, wherein:


$R_e$ is hydrogen, alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, or a monovalent amino protecting group; and

$R_6$ is hydrogen, hydroxy, or amino; or

acyloxy$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, amido$_{(C\leq 8)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt thereof.

8. The compound according to any one of claims 1 and 5-7, wherein the compound is further defined as:




(II-B),

wherein:

$R_1$ is hydrogen; or

alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below;


$R_2$ is $-NR_cR_d$, wherein:

$R_c$ and $R_d$ are each independently hydrogen, alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, acyl$_{(C\leq 8)}$, substituted acyl$_{(C\leq 8)}$, or a monovalent amino protecting group; or

$R_1$ and $R_2$ are taken together as defined below; or

$R_1$ and $R_2$, when taken together with the nitrogen atom of the $-NR_1R_2$ group, is *N*-heteroaryl$_{(C\leq 8)}$, substituted *N*-heteroaryl$_{(C\leq 8)}$, *N*-heterocycloalkyl$_{(C\leq 8)}$, or 3-oxo-1-(*t*-butoxycarbonyl)pyrazolidin-2-yl; or

substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:





,

wherein:

n is 0, 1, 2, or 3;

$R_a$ is hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; or

substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:



,

wherein:


the bond between atoms a and b is a single bond or a double bond;

m is 0, 1, 2, or 3; and

$X_1$ is $-CH_2-$, $-O-$, or $-N(R_b)-$, wherein:

$R_b$ is hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$; or

substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:



,

wherein:

p is 0 or 1;

q is 0 or 1; and

$X_2$ is $-CH_2-$, $-O-$, or $-N(R_e)-$, wherein:

$R_e$ is hydrogen, alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, or a monovalent amino protecting group; and

or a pharmaceutically acceptable salt thereof.

9. The compound according to any one of claims 1-4, wherein:

$R_1$ is hydrogen, or alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, a monovalent amino protecting group, or $-C(O)R_4$, wherein:

$R_4$ is hydrogen; or

alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocycloalkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups.

10. The compound according to any one of claims 1-4, wherein:

$R_1$ is $alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, a monovalent amino protecting group, or $-C(O)R_4$, wherein:

$R_4$ is hydrogen; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $cycloalkoxy_{(C\leq 8)}$, $cycloalkylamino_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, or a substituted version of any one of these groups.

11. The compound according to any one of claims 1-4, wherein:

$R_1$ is hydrogen, $alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, or $-C(O)R_4$, wherein:

$R_4$ is hydrogen; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $cycloalkoxy_{(C\leq 8)}$, $cycloalkylamino_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, or a substituted version of any one of these groups.

12. The compound according to any one of claims 1-4, wherein:

$R_1$ is hydrogen, substituted $alkyl_{(C\leq 8)}$, or $-C(O)R_4$, wherein

$R_4$ is hydrogen; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $cycloalkoxy_{(C\leq 8)}$, $cycloalkylamino_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, or a substituted version of any one of these groups.

13. The compound according to any one of claims 1- 4, wherein:

$R_1$ is hydrogen, $alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, or $-C(O)R_4$, wherein:

$R_4$ is hydrogen; or

$alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $cycloalkoxy_{(C\leq 8)}$, $cycloalkylamino_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, or a substituted version of any one of these groups.

14. The compound according to any one of claims 1-4, wherein:

$R_1$ is hydrogen, $alkyl_{(C\leq 8)}$, substituted $alkyl_{(C\leq 8)}$, or $-C(O)R_4$, wherein:

$R_4$ is hydrogen; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $cycloalkoxy_{(C\leq 8)}$, $cycloalkylamino_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, or a substituted version of any one of these groups.

15. The compound according to any one of claims 1-4, wherein:

$R_1$ is hydrogen, substituted alkyl$_{(C\leq 8)}$, or $-C(O)R_4$, wherein:

$R_4$ is hydrogen; or

alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocycloalkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups.

16. The compound according to any one of claims 1-9, 11, 13, and 14, wherein $R_1$ is hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$.

17. The compound according to any one of claims 1-9, and 11-16, wherein $R_1$ is hydrogen.

18. The compound according to any one of claims 1-11, 13, 14 and 16, wherein $R_1$ is alkyl$_{(C\leq 8)}$ or substituted alkyl$_{(C\leq 8)}$.

19. The compound according to any one of claims 1-11, 13, 14, 16, and 18, wherein $R_1$ is alkyl$_{(C\leq 8)}$.

20. The compound according to any one of claims 1-11, 13, 14, 16, 18 and 19, wherein $R_1$ is methyl.

21. The compound according to any one of claims 1-4 and 9-20, wherein:
$R_2$ is substituted alkyl$_{(C\leq 8)}$ or $-C(O)R_5$, wherein:

$R_5$ is hydrogen; or

alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocyclo-alkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups.

22. The compound according to any one of claims 1-4 and 9-20, wherein:
$R_2$ is alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, or $-C(O)R_5$, wherein:

$R_5$ is hydrogen; or

alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocycloalkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups.

23. The compound according to any one of claims 1-4 and 9-20, wherein:
$R_2$ is alkyl$_{(C\leq 8)}$, substituted alkyl$_{(C\leq 8)}$, or $-C(O)R_5$, wherein:

$R_5$ is hydrogen; or

alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocycloalkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups.

24. The compound according to any one of claims 1-4 and 9-20, wherein:

$R_2$ is substituted alkyl$_{(C\leq 8)}$, or $-C(O)R_5$, wherein:

$R_5$ is hydrogen; or

alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, cycloalkyl$_{(C\leq 8)}$, cycloalkoxy$_{(C\leq 8)}$, cycloalkylamino$_{(C\leq 8)}$, heterocycloalkyl$_{(C\leq 8)}$, or a substituted version of any one of these groups.

25. The compound according to any one of claims 1-4, 9-20, 22 and 23, wherein $R_2$ is alkyl$_{(C\leq 8)}$ or substituted alkyl$_{(C\leq 8)}$.

26. The compound according to any one of claims 1-4, 9-20, 22, 23 and 25, wherein $R_2$ is alkyl$_{(C\leq 8)}$.

27. The compound according to any one of claims 1-4, 9-20, 22, 23, 25 and 26, wherein $R_2$ is methyl.

28. The compound according to any one of claims 1-4, 9-21, and 23, wherein $R_5$ is alkyl$_{(C\leq 8)}$ or substituted alkyl$_{(C\leq 8)}$.

29. The compound according to any one of claims 1-4, 9-21, 23 and 28, wherein $R_5$ is alkyl$_{(C\leq 8)}$.

30. The compound according to any one of claims 1-4, 9-21, 23, 28 and 29, wherein $R_5$ is methyl or ethyl.

31. The compound according to any one of claims 1-4, 9-21, 23 and 28, wherein $R_5$ is substituted alkyl$_{(C\leq 8)}$.

32. The compound according to any one of claims 1-4, 9-21, 23, 28 and 31, wherein $R_5$ is 1,1-difluoroeth-1-yl, difluoromethyl, or fluoromethyl.

33. The compound according to any one of claims 1-4, and 9-24, wherein $R_5$ is cycloalkyl$_{(C\leq 8)}$ or substituted cycloalkyl$_{(C\leq 8)}$.

34. The compound according to any one of claims 1-4, 9-24 and 33, wherein $R_5$ is cycloalkyl$_{(C\leq 8)}$.

35. The compound according to any one of claims 1-4, 9-24, 33 and 34 wherein $R_5$ is cyclopropyl.

36. The compound according to any one of claims 1-4 and 9-22, wherein $R_5$ is alkylamino$_{(C\leq 8)}$.

37. The compound according to any one of claims 1-4, 9-22 and 36, wherein $R_5$ is methylamino.

38. The compound according to any one of claims 1-8, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is *N*-heteroaryl$_{(C\leq 8)}$, substituted *N*-heteroaryl$_{(C\leq 8)}$, *N*-heterocycloalkyl$_{(C\leq 8)}$, or substituted *N*-heterocycloalkyl$_{(C\leq 8)}$.

39. The compound according to any one of claims 1-8 and 38, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is *N*-heteroaryl$_{(C\leq 8)}$ or substituted *N*-heteroaryl$_{(C\leq 8)}$.

40. The compound according to any one of claims 1-8, 38, and 39, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is *N*-heteroaryl$_{(C\leq 8)}$.


41. The compound according to any one of claims 1-8 and 38-40, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is 3,5-dimethylpyrazol-1-yl, triazol-1-yl, 4-methyltriazol-1-yl, 1,2,4-triazol-1-yl, 1*H*-1,2,4-triazol-1-yl, 4*H*-1,2,4-triazol-4-yl, pyrazol-1-yl, tetrazol-1-yl, or imidazol-1-yl.

42. The compound according to any one of claims 1-8, 38, and 39, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is substituted *N*-heteroaryl$_{(C\leq 8)}$.

43. The compound according to any one of claims 1-8, 38, 39, and 42, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is 4-methylcarbamoyl-triazol-1-yl, 4-(hydroxymethyl)triazol-1-yl, 4-(fluoromethyl)triazol-1-yl, 4-(difluoromethyl)triazol-1-yl, 5-(trifluoromethyl)-1*H*-pyrazol-1-yl, or 3-(trifluoromethyl)-1*H*-pyrazol-1-yl.

44. The compound according to any one of claims 1-8 and 38, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is *N*-heterocycloalkyl$_{(C\leq 8)}$ or substituted *N*-heterocycloalkyl$_{(C\leq 8)}$.


45. The compound according to any one of claims 1-8, 38, and 44, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is *N*-heterocycloalkyl$_{(C\leq 8)}$.

46. The compound according to any one of claims 1-8, 38, 44, and 45, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is oxazolidin-3-yl, azetidin-1-yl, or .

47. The compound according to any one of claims 1-8, 38, and 44, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is substituted *N*-heterocycloalkyl$_{(C\leq 8)}$.

48. The compound according to any one of claims 1-8, 38, 44, and 47, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group, wherein the $-NR_1R_2$ group is imidazolidin-2-one-1-yl, 3-methylimidazolidin-2-one-1-yl, oxazolidin-2-one-3-yl, azetidin-2-one-1-yl, pyrrolidin-2-one-1-yl, 3-oxoazetidin-1-yl, 3-oxopyrazolidin-1-yl, 5-oxopyrazolidin-1-yl, 3-hydroxyazetidin-1-yl, 3-fluoroazetidin-1-yl, 2-oxooxazolidin-3-yl, 2-oxooxazol-3(2*H*)-yl, 2-oxo-2,3-dihydro-1*H*-imidazol-1-yl, 3-methyl-2-oxo-2,3-dihydro-1H-imidazol-1-yl, 3,3-difluoroazetidin-1-yl, 4-methyl-2,5-dioxopiperazin-1-yl, or 4-methyl-3-oxopiperazin-1-yl.

49. The compound according to any one of claims 1-8, 38, 44 and 47, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:





wherein:

n is 0, 1, 2, or 3;

$R_a$ is hydrogen, alkyl$_{(C\leq 5)}$, or substituted alkyl$_{(C\leq 5)}$.

50. The compound according to any one of claims 1-8, 38, 44, 47, and 49, wherein the $-NR_1R_2$ group is 3-oxopyrazolidin-1-yl or 5-oxopyrazolidin-1-yl.

51. The compound according to any one of claims 1-8, 38, 44, and 47, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:




wherein:


the bond between atoms a and b is a single bond or a double bond;

m is 0, 1, 2, or 3; and

$X_1$ is $-CH_2-$, $-O-$ or $-N(R_b)-$, wherein:

$R_b$ is hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$.

52. The compound according to any one of claims 1-8, 38, 44, and 47, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group and is substituted *N*-heterocycloalkyl$_{(C\leq 8)}$, further wherein the $-NR_1R_2$ group is of the formula:



or



,

wherein:

p is 0 or 1;


q is 0 or 1; and

$X_2$ is $-CH_2-$, $-O-$, or $-N(R_e)-$, wherein:


$R_e$ is hydrogen, alkyl$_{(C\leq 8)}$, or substituted alkyl$_{(C\leq 8)}$.

53. The compound according to any one of claims 1-8, wherein $R_1$ and $R_2$ are taken together with the nitrogen atom of the $-NR_1R_2$ group, wherein the $-NR_1R_2$ group is 3-oxo-1-(tert-butoxycarbonyl)pyrazolidin-2-yl.


54. The compound according to any one of claims 1-53, wherein the compound is further defined as:




,




,




,















,















,
















,



,

,

,

,

,

,

,

,

,

HCl
,

,

,


,

,

,

,

,

,

,

,

,

,

,

,













,

,


,

,

,

,

,

,

,

,

,

,

,

,

,











,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,



,

,

,

,

,

,

,

,

, or

;

or a pharmaceutically acceptable salt of any of these formulas.

55. The compound according to any one of claims 1-53, wherein the compound is further defined as:





or




.

56. A compound of the formula:




;

or a pharmaceutically acceptable salt of any of these formulas.

57. A pharmaceutical composition comprising:

(A) a compound according to any one of claims 1-56; and

(B) an excipient.

58. Use of the compound according to any one of claims 1-56 or the pharmaceutical composition according to claim 57 for the preparation of a medicament for the treatment or prevention of a disease or disorder.

59. The use of claim 58, wherein the medicament is formulated to be administered to a human.

60. The use of claim 58, wherein the disease or disorder is a condition associated with inflammation and/or oxidative stress.

61. Use of the compound according to any one of claims 1-56 or the pharmaceutical composition according to claim 57 for the preparation of a medicament for inhibiting nitric oxide production.